Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis

PHASE2RecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

February 8, 2024

Primary Completion Date

February 28, 2026

Study Completion Date

February 28, 2026

Conditions
Idiopathic Pulmonary Fibrosis (IPF)
Interventions
DRUG

INS018_055

"Pharmaceutical formulation: Capsules~Mode of Administration: Oral"

DRUG

Placebo

"Pharmaceutical formulation: Capsules~Mode of Administration: Oral"

Trial Locations (12)

19140

RECRUITING

Temple University Hospital-Temple Lung Center, Philadelphia

35294

RECRUITING

University of Alabama at Birmingham, Birmingham

75071

RECRUITING

Research Centers of America, McKinney

85258

RECRUITING

HonorHealth Research Institute, Scottsdale

90033

RECRUITING

Keck School of Medicine of USC, Los Angeles

34747-1818

RECRUITING

Florida Lung Asthma and Sleep Specialist, Celebration

32803-5727

RECRUITING

Central Florida Pulmonary Group, P.A. (CFPG) - Downtown Orlando, Orlando

27103-4007

RECRUITING

Southeastern Research Center, Winston-Salem

73104-5417

RECRUITING

University of Oklahoma Health Sciences Center (OUHSC), Oklahoma City

29201-2953

RECRUITING

Bogan Sleep Consultants, LLC, Columbia

75235-6243

RECRUITING

University of Texas Southwestern Medical Center, Dallas

75069-1898

RECRUITING

Metroplex Pulmonary and Sleep Center, McKinney

All Listed Sponsors
lead

InSilico Medicine Hong Kong Limited

INDUSTRY